Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
64
DMAC Quote, Financials, Valuation and Earnings
Last price:
$8.80
Seasonality move
:
25.24%
Day range:
$8.61 - $8.96
52-week range:
$3.19 - $9.23
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
8.86x
Volume:
240.8K
Avg. volume:
437.5K
1-year change:
63.5%
Market cap:
$457.2M
Revenue:
--
EPS (TTM):
-$0.72
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
-- | -$0.16 | -- | -2.44% | $15.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $7.00 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
$8.78 | $15.50 | $457.2M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$1.21 | $0.85 | $152.5M | 2.03x | $0.80 | 0% | 2.35x |
|
NNVC
NanoViricides, Inc.
|
$1.23 | $7.00 | $22.1M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $727K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.23 | $7.00 | $7.6M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
0.51% | 2.462 | 0.07% | 10.50x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DMAC
DiaMedica Therapeutics, Inc.
|
-$18K | -$9M | -78.63% | -79.25% | -- | -$6.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
DiaMedica Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns DMAC or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of -255.85%. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About DMAC or NBY?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 76.54%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -29.75%. Given that DiaMedica Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe DiaMedica Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is DMAC or NBY More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock DMAC or NBY?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or NBY?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 2.03x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 2.35x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M NBYNovaBay Pharmaceuticals, Inc.2.35x 2.03x $521K -$1.3M
-
Which has Higher Returns DMAC or NNVC?
NanoViricides, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About DMAC or NNVC?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 76.54%. On the other hand NanoViricides, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 469.11%. Given that NanoViricides, Inc. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 NNVCNanoViricides, Inc.0 0 0 -
Is DMAC or NNVC More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock DMAC or NNVC?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or NNVC?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns DMAC or OGEN?
Oragenics, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About DMAC or OGEN?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 76.54%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 126.37%. Given that Oragenics, Inc. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Oragenics, Inc. is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 OGENOragenics, Inc.1 0 0 -
Is DMAC or OGEN More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock DMAC or OGEN?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or OGEN?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns DMAC or PTN?
Palatin Technologies has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M PTNPalatin Technologies-- -- -- -
What do Analysts Say About DMAC or PTN?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 76.54%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 PTNPalatin Technologies0 0 0 -
Is DMAC or PTN More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock DMAC or PTN?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or PTN?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is higher than Palatin Technologies's net income of --. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns DMAC or TOVX?
Theriva Biologics, Inc. has a net margin of -- compared to DiaMedica Therapeutics, Inc.'s net margin of --. DiaMedica Therapeutics, Inc.'s return on equity of -79.25% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital DMACDiaMedica Therapeutics, Inc.-- -$0.17 $51.9M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About DMAC or TOVX?
DiaMedica Therapeutics, Inc. has a consensus price target of $15.50, signalling upside risk potential of 76.54%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3004.21%. Given that Theriva Biologics, Inc. has higher upside potential than DiaMedica Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than DiaMedica Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DMACDiaMedica Therapeutics, Inc.5 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is DMAC or TOVX More Risky?
DiaMedica Therapeutics, Inc. has a beta of 1.312, which suggesting that the stock is 31.167% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock DMAC or TOVX?
DiaMedica Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DiaMedica Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DMAC or TOVX?
DiaMedica Therapeutics, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. DiaMedica Therapeutics, Inc.'s net income of -$8.6M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, DiaMedica Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DiaMedica Therapeutics, Inc. is -- versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DMACDiaMedica Therapeutics, Inc.-- -- -- -$8.6M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
